KemPharm (NASDAQ:KMPH) Upgraded to “Hold” by Zacks Investment Research

KemPharm (NASDAQ:KMPHGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

A number of other equities analysts have also commented on KMPH. HC Wainwright upgraded KemPharm from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $10.00 to $11.00 in a research note on Monday, January 31st. StockNews.com assumed coverage on KemPharm in a report on Thursday, March 31st. They set a “hold” rating on the stock.

NASDAQ:KMPH opened at $4.54 on Thursday. KemPharm has a 52-week low of $4.10 and a 52-week high of $15.70. The stock has a 50-day simple moving average of $4.99 and a 200 day simple moving average of $6.94.

KemPharm (NASDAQ:KMPHGet Rating) last issued its quarterly earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). KemPharm had a positive return on equity of 7.03% and a negative net margin of 29.86%. On average, research analysts predict that KemPharm will post -0.11 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of KMPH. Strategic Asset Management LLC lifted its position in shares of KemPharm by 16.7% during the first quarter. Strategic Asset Management LLC now owns 40,087 shares of the specialty pharmaceutical company’s stock worth $202,000 after acquiring an additional 5,739 shares in the last quarter. City State Bank bought a new position in shares of KemPharm during the fourth quarter valued at about $117,000. BlackRock Inc. grew its stake in shares of KemPharm by 14.1% during the fourth quarter. BlackRock Inc. now owns 2,235,542 shares of the specialty pharmaceutical company’s stock valued at $19,472,000 after buying an additional 276,104 shares during the last quarter. Mystic Asset Management Inc. bought a new position in shares of KemPharm during the fourth quarter valued at about $626,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of KemPharm by 13.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 190,790 shares of the specialty pharmaceutical company’s stock worth $1,662,000 after purchasing an additional 22,101 shares during the period. Institutional investors and hedge funds own 32.39% of the company’s stock.

KemPharm Company Profile (Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Further Reading

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.